Two large hospitals, Cleveland Clinic and Mount Sinai, have decided against administering Aduhelm for patients following controversy around the Alzheimer’s drug’s FDA approval drug…
Will Medicare cover Alzheimer’s drugs like Aduhelm? That decision-making process is underway. This week, the U.S. government embarked on the formal review process to…
Image: Aduhelm, Biogen/AP. The head of the FDA, Dr. Janet Woodcock, calls for investigation into the agency’s own controversial approval of Biogen’s Aduhelm, the…
Following sharp criticisms of the FDA’s broad approval of Aduhelm for all patients with Alzheimer’s, the agency has narrowed the drug’s label to those…
The FDA will hasten the review of two more new Alzheimer’s drug candidates, Eli Lilly & Co.’s donanemab and Biogen and Eisai’s lecanemab. Today,…
Image: Aduhelm, Biogen/AP. “The approach I’ve been taking is that each decision about whether or not to offer this as a treatment has to…
Biogen’s recently FDA-approved drug Aduhelm costs an upward of $56,000 per year, and this may have a domino effect of impacts: “If Aduhlem is…